Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B1962 in advanced colorectal cancer
NCT06838546Phase 2Not yet recruiting
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Jan 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of B1962 in colorectal cancer (CRC), sponsored by Tasly Biopharmaceuticals Co., Ltd.. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
B1962
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06838546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06838546.